Preoperative serum tumor marker levels in gastric cancer

Pakistan Journal of Medical Sciences

Volumn 30, Issue 1, 2014, Pages 145-149

  Polat, Erdal ^a   Duman, Ugur ^b   Duman, Mustafa ^a   Peker, Kivanc Derya ^a   Akyuz, Cebrail ^a   Yasar, Necdet Fatih ^a   Uzun, Orhan ^a   Akbulut, Sabiye ^a   Bostanci, Erdal Birol ^c   Yol, Sinan ^a  

^a Kartal Kosuyolu High Speciality Training and Research Hospital   (Turkey)

^b Bursa Sevket Yilmaz Training and Research Hospital   (Turkey)

^c TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

Gastric cancer; Peritoneal carcinomatozis; Serum tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CELL LINE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CARCINOMATOSIS; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STOMACH CANCER; TUMOR DIFFERENTIATION;

EID: 84928608973     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.301.3968     Document Type: Article

References (52)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
2. Lochhead P, ElOmar EM. Gastric cancer. Br Med Bull. 2008;85:87-100.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
4. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467-477.
5. Liakakos T, Roukos DH: More controversy than ever-challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol. 2008;15(4):956-960.
6. McCulloch P, Nita ME, Kazi H, GamaRodrigues J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev. 2004: CD001964.
7. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
8. Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12:6-22.
9. Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O’Brien M, et al. The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer. Eur J Cancer. 1996;32A:63-68.
10. Nakane Y, Okamura S, Akehira K, Boku T, Okusa T, Tanaka K, et al. Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients. Cancer. 1994;73:2703-2708.
11. Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, et al. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol. 1996;91:49-53.
12. Ikeda Y, Oomori H, Koyanagi N, Mori M, Kamakura T, Minagawa S, et al. Prognostic value of combination assays for CEA and CA 19-9 in gastric cancer. Oncology. 1995;52:483-486.
13. Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N, et al. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol. 1999;29:550-555.
14. Marrelli D, Roviello F, De Stefano A, Farnetani M, Garosi L, Messano A, et al. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology. 1999;57:55-62.
15. Mattar R, Alves de Andrade CR, DiFavero GM, Gama-Rodrigues JJ, Laudanna AA. Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo. 2002;57(3):89-92.
16. Ikeguchi M, Katano K, Saitou H, Tsujitani S, Maeta M, Kaibara N. Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma. Hepatogastroenterology. 1997;44:866-871.
17. Ilhan N, Ilhan N, Ilhan Y, Akbulut H, Kucuksu M. C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol. 2004;10:1115-1120.
18. Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, et al. Serum interleukin-6 and-10 levels in patients with gastric cancer. Gastric Cancer. 2009;12:95-100.
19. Mroczko B, Groblewska M, Lukaszewicz-Zajac M, Bandurski R, Kedra B, Szmitkowski M. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. Clin Chem Lab Med. 2009;47:1133-1139.
20. Mroczko B, Wereszczynska-Siemiatkowska U, Groblewska M, Lukaszewicz M, Szmitkowski M, Gryko M, et al. The diagnostic value of hematopoietic cytokines measurement in the sera of gastric cancer and gastric ulcer patients. Clin Chim Acta. 2006;374:165-167.
21. Kochi M, Fujii M, Kanamori N, Kaiga T, Kawakami T, Aizaki K, et al. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer. 2000;3:177-186.
22. Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142-145.
23. Staab HJ, Anderer FA, Brummendorf T, Hornung A, Fischer R. Prognostic value of preoperative serum CEA level compared to clinical staging: II. Stomach cancer. Br J Cancer. 1982;45:718-727.
24. Dittrich C, Jakesz R, Havelec L, Lenzhofer R, Breyer S, Moser K. Carcinoembryonic antigen (CEA) plasma level determination in the management of gastric cancer patients. Cancer Detect Prev. 1985;8:181-187.
25. Tamada R, Hiramoto Y, Tsujitani S, Nozuka T, Okamura T, Masuda H, et al. Serum CEA levels facilitate detection of recurrences of cancer in patients after gastrectomy. Jpn J Surg. 1985;15:23-29.
26. Shimizu N, Wakatsuki T, Murakami A, Yoshioka H, Hamazoe R, Kanayama H, et al. Carcinoembryonic antigen in gastric cancer patients. Oncology. 1987;44:240-244.
27. Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M. Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection. Cancer Res. 1990;50:3952-3955.
28. Maehara Y, Kusumoto T, Takahashi I, Kakeji Y, Baba H, Akazawa K, et al. Predictive value of preoperative carcinoembryonic antigen levels for the prognosis of patients with well-differentiated gastric cancer. A multivariate analysis. Oncology. 1994;51:234-237.
29. Sakamoto J, Nakazato H, Teramukai S, Ohashi Y, Takahashi Y, Mai M, et al. Association between preoperative plasma CEA levels and the prognosis of gastric cancer following curative resection. Tumor Marker Committee, Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan. Surg Oncol. 1996;5:133-139.
30. Heptner G, Domschke S, Domschke W. Comparison of CA 72-4 with CA 19-9 and carcinoembryonic antigen in the serodiagnostics of gastrointestinal malignancies. Scand J Gastroenterol. 1989;24:745-750.
31. Kornek G, Depisch D, Temsch EM, Scheithauer W. Comparative analysis of cancer-associated antigen CA-195, CA 19-9 and carcinoembryonic antigen in diagnosis, followup and monitoring of response to chemotherapy in patients with gastrointestinal cancer. J Cancer Res Clin Oncol. 1991;117:493-496.
32. Staab HJ, Anderer FA, Brummendorf T, Fischer R. Prognostic significance of preoperative carcinoembryonic antigen in stomach and colorectal cancer. Cancer Detect Prev. 1983;6:149-153.
33. Janssen CW, Orjasaeter H. Carcinoembryonic antigen in patients with gastric carcinoma. Eur J Surg Oncol. 1986;12:19-23.
34. Koga T, Kano T, Souda K, Oka N, Inokuchi K. The clinical usefulness of preoperative CEA determination in gastric cancer. Jpn J Surg. 1987;17:342-347.
35. Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer. 1995;75:451-456.
36. Nishiyama M, Takashima I, Tanaka T, Yoshida K, Toge T, Nagata N. Carcinoembryonic antigen levels in the peritoneal cavity: useful guide to peritoneal recurrence and prognosis for gastric cancer. World J Surg. 1995;19:133-137; discussion 137.
37. Duraker N, Celik AN. The prognostic significance of reoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001;76:266-271.
38. Ishigami S, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, et al. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol. 2001;32:41-44.
39. Mori M, Sakaguchi H, Akazawa K, Tsuneyoshi M, Sueishi K, Sugimachi K: Correlation between metastatic site, histological type, and serum tumor markers of gastric carcinoma. Hum Pathol. 1995;26:504-508.
40. Qiu MZ, Lin JZ, Wang ZQ, Wang FH, Pan ZZ, Luo HY, et al. Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. Int J Biol Markers. 2009;24:258-264.
41. Guadagni F, Roselli M, Amato T, Cosimelli M, Perri P, Casale V, et al. CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma. Cancer Res. 1992;52:1222-1227.
42. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57:327-334.
43. Grimm T, Johnson JP: Ectopic expression of carcinoembryonic antigen by a melanoma cell leads to changes in the transcription of two additional cell adhesion molecules. Cancer Res. 1995;55:3254-3257.
44. Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2012;15:154-161.
45. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21:67-70.
46. Kodera Y, Ito Y, Ito S, Ohashi N, Mochizuki Y, Yamamura Y, et al. Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology. 2007;54:960-963.
47. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
48. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419-423.
49. Nakata B, Hirakawa YSCK, Kato Y, Yamashita Y, Maeda K, Onoda N, et al. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer. 1998;83:2488-2492.
50. Hwang GI, Yoo CH, Sohn BH, Shin JH, Park YL, Kim HD, et al. Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma. Cancer Res Treat. 2004;36:178-181.
51. Fujimura T, Kinami S, Ninomiya I, Kitagawa H, Fushida S, Nishimura G, et al. Diagnostic laparoscopy, serum CA125, and peritoneal metastasis in gastric cancer. Endoscopy. 2002;34:569-574.
52. Kodama I, Koufuji K, Kawabata S, Tetsu S, Tsuji Y, Takeda J, et al. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA. Int Surg. 1995;80:45-48.